These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 15763792)
1. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. Venkatachalam S; Bagratee JS; Moodley J J Obstet Gynaecol; 2004 Oct; 24(7):798-800. PubMed ID: 15763792 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281 [TBL] [Abstract][Full Text] [Related]
3. Depo medroxyprogesterone acetate (DMPA) therapy for uterine myomata prior to surgery. Johnson N; Fletcher H; Reid M Int J Gynaecol Obstet; 2004 May; 85(2):174-6. PubMed ID: 15099785 [No Abstract] [Full Text] [Related]
4. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital. Woodhead N; Pounds R; Irani S; Pradhan P J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144 [TBL] [Abstract][Full Text] [Related]
5. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial. Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549 [TBL] [Abstract][Full Text] [Related]
6. Ulipristal acetate versus placebo for fibroid treatment before surgery. Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E; N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075 [TBL] [Abstract][Full Text] [Related]
8. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871 [TBL] [Abstract][Full Text] [Related]
9. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study. Bradley LD; Singh SS; Simon J; Gemzell-Danielsson K; Petersdorf K; Groettrup-Wolfers E; Ren X; Zvolanek M; Seitz C Fertil Steril; 2019 Feb; 111(2):240-248. PubMed ID: 30527839 [TBL] [Abstract][Full Text] [Related]
10. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review. Donnez J; Courtoy GE; Donnez O; Dolmans MM Reprod Biomed Online; 2018 Aug; 37(2):216-223. PubMed ID: 29706284 [TBL] [Abstract][Full Text] [Related]
11. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604 [TBL] [Abstract][Full Text] [Related]
12. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160 [TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy. Brun JL; Rajaonarison J; Froeliger A; Monseau-Thiburce AC; Randriamboavonjy R; Vogler A Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():13-18. PubMed ID: 29328939 [TBL] [Abstract][Full Text] [Related]
15. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Al-Hendy A; Venturella R; Arjona Ferreira JC; Li Y; Soulban G; Wagman RB; Lukes AS Am J Obstet Gynecol; 2023 Dec; 229(6):662.e1-662.e25. PubMed ID: 37666383 [TBL] [Abstract][Full Text] [Related]
16. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357 [TBL] [Abstract][Full Text] [Related]
17. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415 [TBL] [Abstract][Full Text] [Related]
18. Fibroid-related menorrhagia: treatment with superselective embolization of the uterine arteries and midterm follow-up. Pelage JP; Le Dref O; Soyer P; Kardache M; Dahan H; Abitbol M; Merland JJ; Ravina JH; Rymer R Radiology; 2000 May; 215(2):428-31. PubMed ID: 10796920 [TBL] [Abstract][Full Text] [Related]
19. Uterine artery ligation for management of uterine fibroids. Akinola OI; Fabamwo AO; Ottun AT; Akinniyi OA Int J Gynaecol Obstet; 2005 Nov; 91(2):137-40. PubMed ID: 16168993 [TBL] [Abstract][Full Text] [Related]
20. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Scialli AR; Jestila KJ Fertil Steril; 1995 Aug; 64(2):313-20. PubMed ID: 7615109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]